Work

Evaluation of Ameliorative Efficacy of Carboplatin with Pioglitazone Through Adiponectin Augmentation by Activating PPAR-γ in High-Fat Diet-Induced Ovarian Cancer in Mice

Year: 2025

Type: article

Abstract: Carboplatin is one of the preferred treatments for ovarian cancer. To improve the therapeutic effectiveness of carboplatin in ovarian cancer, the novel combination therapy of carboplatin with the peroxisome proliferator-activated receptor-gamma agonist pioglitazone was studied in a high-fat diet-induced ovarian cancer model. Thirty Swiss Albino mice (20-35 g) were randomly divided into five groups. Group I received a regular diet, while groups II-V were fed a high-fat diet, with group II serving as the disease control. Groups III-V received carboplatin (133 mg/kg), carboplatin (133 mg/kg) plus pioglitazone (3 mg/kg), and carboplatin (133 mg/kg) plus pioglitazone (9 mg/kg), respectively, for 14 weeks. On day 56 of the study, cancer induction was confirmed by measuring serum lipid profile, pro-inflammatory cytokines, and adiponectin levels. Following this, drug treatment was administered for 6 weeks. On day 98, treatment efficacy was evaluated through serum lipid profiles and pro-inflammatory cytokine levels, and confirmed by ovarian histological studies. The combination therapy of carboplatin and pioglitazone significantly altered serum lipid profiles (TC, TG, LDL, and HDL) and pro-inflammatory cytokine (IL-6, TNF-α, and MCP-1) levels. Additionally, it increased adiponectin levels by activating the PPAR-γ receptor, compared to the disease control. The combination of carboplatin with the PPAR-γ activating ligand pioglitazone enhances the efficacy of carboplatin in ovarian carcinoma by increasing plasma adiponectin levels, which effectively reduces cytokines and chemokines responsible for tumor progression in obesity-induced ovarian cancer.

Source: Macedonian Veterinary Review

DOI: 10.2478/macvetrev-2025-0031